Bevacizumab with or after chemotherapy for platinum-resistant recurrent ovarian cancer: exploratory analyses of the AURELIA trial.

MLA

Bamias, A., et al. “Bevacizumab with or after Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: Exploratory Analyses of the AURELIA Trial.” Annals of Oncology, vol. 28, no. 8, Aug. 2017, pp. 1842–48. EBSCOhost, https://doi.org/10.1093/annonc/mdx228.

APA

Bamias, A., Gibbs, E., Lee, C. K., Davies, L., Dimopoulos, M., Zagouri, F., Veillard, A.-S., Kosse, J., Santaballa, A., Mirza, M. R., Tabaro, G., Vergote, I., Bloemendal, H., Lykka, M., Floquet, A., Gebski, V., & Pujade-Lauraine, E. (2017). Bevacizumab with or after chemotherapy for platinum-resistant recurrent ovarian cancer: exploratory analyses of the AURELIA trial. Annals of Oncology, 28(8), 1842–1848. https://doi.org/10.1093/annonc/mdx228

Chicago

Bamias, A., E. Gibbs, C. Khoon Lee, L. Davies, M. Dimopoulos, F. Zagouri, A.-S. Veillard, et al. 2017. “Bevacizumab with or after Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: Exploratory Analyses of the AURELIA Trial.” Annals of Oncology 28 (8): 1842–48. doi:10.1093/annonc/mdx228.